Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.
Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joiningSilence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.